Thoroughbred Financial Services LLC grew its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 19,447.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,805,392 shares of the medical research company’s stock after buying an additional 1,796,156 shares during the quarter. Thoroughbred Financial Services LLC owned 0.30% of Amgen worth $180,539,000 at the end of the most recent quarter.
Several other institutional investors also recently bought and sold shares of AMGN. Capital Financial Planning LLC purchased a new position in Amgen in the 4th quarter worth $27,000. Arbor Wealth Management LLC grew its holdings in Amgen by 154.5% in the 2nd quarter. Arbor Wealth Management LLC now owns 168 shares of the medical research company’s stock worth $31,000 after acquiring an additional 102 shares during the last quarter. Next Capital Management LLC bought a new stake in Amgen in the 4th quarter worth $33,000. C J Advisory Inc bought a new stake in Amgen in the 1st quarter worth $40,000. Finally, Clarfeld Financial Advisors LLC bought a new stake in Amgen in the 4th quarter worth $41,000. Hedge funds and other institutional investors own 77.26% of the company’s stock.
NASDAQ:AMGN traded down $1.66 during mid-day trading on Thursday, hitting $174.11. 1,724,407 shares of the company’s stock were exchanged, compared to its average volume of 2,922,055. Amgen, Inc. has a one year low of $166.30 and a one year high of $210.19. The company has a debt-to-equity ratio of 2.71, a quick ratio of 2.53 and a current ratio of 2.77. The company has a fifty day moving average price of $180.28. The stock has a market cap of $107.27 billion, a P/E ratio of 12.09, a PEG ratio of 2.15 and a beta of 1.16.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, April 30th. The medical research company reported $3.56 EPS for the quarter, topping the consensus estimate of $3.45 by $0.11. Amgen had a net margin of 34.00% and a return on equity of 71.02%. The business had revenue of $5.56 billion for the quarter, compared to analyst estimates of $5.55 billion. During the same quarter in the previous year, the firm posted $3.47 earnings per share. Amgen’s quarterly revenue was up .1% on a year-over-year basis. Equities analysts predict that Amgen, Inc. will post 13.85 earnings per share for the current fiscal year.
A number of equities research analysts have issued reports on AMGN shares. Cantor Fitzgerald reissued a “hold” rating and issued a $41.00 price target on shares of Mylan in a report on Monday, April 1st. Cowen reissued a “hold” rating and issued a $103.00 price target on shares of United Therapeutics in a report on Wednesday, May 1st. Zacks Investment Research raised shares of GreenTree Hospitality Group from a “sell” rating to a “hold” rating in a report on Monday, April 15th. Oppenheimer set a $210.00 price target on shares of Amgen and gave the stock a “buy” rating in a report on Friday, May 24th. Finally, Royal Bank of Canada reissued a “neutral” rating and issued a $192.00 price target on shares of Amgen in a report on Tuesday, May 21st. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $208.10.
In related news, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $175.68, for a total transaction of $351,360.00. Following the sale, the director now owns 16,219 shares of the company’s stock, valued at $2,849,353.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 6,000 shares of company stock worth $1,077,980 in the last three months. 0.25% of the stock is currently owned by insiders.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.